Published by Coherent Market Insights
Posted on September 22, 2021
Coherent Market Insights recently published an in depth study of Antiandrogen Monotherapy Market covering interesting aspects of the market with supporting development scenarios starting from 2021-2027. The report delivers the clean elaborated structure of the Market comprising each and each business-related information of the market at a worldwide level. the entire range of data associated with the worldwide Market is obtained through various sources and this obtained bulk of the knowledge is arranged, processed, and represented by a gaggle of specialists through the appliance of various methodological techniques and analytical tools like SWOT analysis to get an entire set of trade-based study regarding the Antiandrogen Monotherapy.
Request PDF With Detailed Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3810
This report assesses the growth rate and the market value on the basis of the key market dynamics, as well as the growth inducing factors. The complete study is based on the up-to-date industry news, growth potentials, and Market trends. It also contains an in-depth analysis of the market and competitive scenario, together with the analysis of the leading competitors.
Antiandrogen monotherapy is one of the newest forms of prostate cancer treatment. Increasing prevalence of prostate cancer is expected to propel growth of antiandrogen monotherapy market. According to the American Cancer Society, in 2019, there will be around 174,650 men with newly diagnosed prostate cancer in the U.S., registering a 6% increase from 2018.
Antiandrogen monotherapy has revolutionized the treatment of prostate cancer as it eliminates the cause of male pattern baldness by restricting and blocking the effect of androgens on the prostate gland. It is also known as hormonal therapy, and its underlying mechanisms are similar to those of surgical removal of the testes, albeit in a very limited scope of function. By blocking the production androgen receptors, the production of DHT, the major androgen in the bloodstream, is significantly reduced. This leads to a gradual but significant reduction in the size of the prostate and its functions such as sperm production, sperm movement and male fertility. Such advantages aid in growth of the antiandrogen monotherapy market.
Increasing geriatric population is expected to aid in growth of the antiandrogen monotherapy market. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Most adult men with prostate cancer undergo an initial phase of antiandrogen monotherapy, a course of drugs that stop the production of DHT. In addition, some of these drugs reduce the activity of the enzyme 5-alpha-reductase, which is responsible for the storage and secretion of testosterone. Testosterone is an androgen, so its absence can severely affect male sexual roles. Testosterone and DHT have been shown to interact in a complex way. Not only does testosterone stimulate the growth of cancerous cells, but it also has other effects on the brain and cognition, and can exacerbate the effects of dementia. The association between testosterone and DHT is more pronounced in elderly men, but there are some reports of sexual dimorphism with antiandrogen monotherapy in young men as well. Therefore, it is possible that the sexual side effects caused by the medication could be exacerbated by antiandrogen deprivation therapy.
One phase of antiandrogen monotherapy is the use of nonsteroidal antiandrogen. These are commonly available over the counter, although some patients do not respond well to this type of treatment. It is important to note that while nonsteroidal antiandrogen relieve pain and inflammation, they are also known to cause stomach ulcers and bleeding, even though this is uncommon with castration. Therefore, whilst this form of treatment can be helpful in reducing the number of prostate cancers that are detectable during a physical examination, it may not be sufficient to prevent development in later years. Such drawbacks limit growth of antiandrogen monotherapy market.
Competitive Analysis:
The key players are highly focusing on innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in optimal strategies. Few Market Key Players are Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Inc., ALZA Corporation, Sanofi SA, GlaxoSmithKline Plc, Amgen Inc, ANI Pharmaceuticals, Inc.
Order a Copy of This Market Report With Instant USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3810
Some Important TOC:
Market Overview
Global Market Landscape by Player
Players Profiles
Global Production, Revenue (Value), Price Trend by Type
Market Analysis by Application
Global Production, Consumption, Export, Import by Region (2013-2021)
Production, Revenue (Value) by Region (2013-2021)
Manufacturing Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Market Dynamics
Global Market Forecast (2021-2027)
Research Findings and Conclusion
Appendix
The following queries are answered in this comprehensive document:
1. What is the market size of the global and regional levels?
2. Which are the top countries and what is their market size?
3. Which are the growth opportunities in the coming years?
4. Which are the top players and what is their market share?
5. Which are the risk factors affecting market growth?
Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Antiandrogen Monotherapy Market 2021 Size, Status and Forecast | Business to 2027 appeared first on Gatorledger.
Coherent Market Insights recently published an in depth study of Antiandrogen Monotherapy Market covering interesting aspects of the market with supporting development scenarios starting from 2021-2027. The report delivers the clean elaborated structure of the Market comprising each and each business-related information of the market at a worldwide level. the entire range of data associated with the worldwide Market is obtained through various sources and this obtained bulk of the knowledge is arranged, processed, and represented by a gaggle of specialists through the appliance of various methodological techniques and analytical tools like SWOT analysis to get an entire set of trade-based study regarding the Antiandrogen Monotherapy.
Request PDF With Detailed Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/3810
This report assesses the growth rate and the market value on the basis of the key market dynamics, as well as the growth inducing factors. The complete study is based on the up-to-date industry news, growth potentials, and Market trends. It also contains an in-depth analysis of the market and competitive scenario, together with the analysis of the leading competitors.
Antiandrogen monotherapy is one of the newest forms of prostate cancer treatment. Increasing prevalence of prostate cancer is expected to propel growth of antiandrogen monotherapy market. According to the American Cancer Society, in 2019, there will be around 174,650 men with newly diagnosed prostate cancer in the U.S., registering a 6% increase from 2018.
Antiandrogen monotherapy has revolutionized the treatment of prostate cancer as it eliminates the cause of male pattern baldness by restricting and blocking the effect of androgens on the prostate gland. It is also known as hormonal therapy, and its underlying mechanisms are similar to those of surgical removal of the testes, albeit in a very limited scope of function. By blocking the production androgen receptors, the production of DHT, the major androgen in the bloodstream, is significantly reduced. This leads to a gradual but significant reduction in the size of the prostate and its functions such as sperm production, sperm movement and male fertility. Such advantages aid in growth of the antiandrogen monotherapy market.
Increasing geriatric population is expected to aid in growth of the antiandrogen monotherapy market. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Most adult men with prostate cancer undergo an initial phase of antiandrogen monotherapy, a course of drugs that stop the production of DHT. In addition, some of these drugs reduce the activity of the enzyme 5-alpha-reductase, which is responsible for the storage and secretion of testosterone. Testosterone is an androgen, so its absence can severely affect male sexual roles. Testosterone and DHT have been shown to interact in a complex way. Not only does testosterone stimulate the growth of cancerous cells, but it also has other effects on the brain and cognition, and can exacerbate the effects of dementia. The association between testosterone and DHT is more pronounced in elderly men, but there are some reports of sexual dimorphism with antiandrogen monotherapy in young men as well. Therefore, it is possible that the sexual side effects caused by the medication could be exacerbated by antiandrogen deprivation therapy.
One phase of antiandrogen monotherapy is the use of nonsteroidal antiandrogen. These are commonly available over the counter, although some patients do not respond well to this type of treatment. It is important to note that while nonsteroidal antiandrogen relieve pain and inflammation, they are also known to cause stomach ulcers and bleeding, even though this is uncommon with castration. Therefore, whilst this form of treatment can be helpful in reducing the number of prostate cancers that are detectable during a physical examination, it may not be sufficient to prevent development in later years. Such drawbacks limit growth of antiandrogen monotherapy market.
Competitive Analysis:
The key players are highly focusing on innovation in production technologies to improve efficiency and shelf life. The best long-term growth opportunities for this sector can be captured by ensuring ongoing process improvements and financial flexibility to invest in optimal strategies. Few Market Key Players are Pfizer Inc., Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, OSI Pharmaceuticals, Inc., Genentech Inc., Bristol-Myers Squibb Company, Novartis AG, Progenics Pharmaceuticals, Inc., ALZA Corporation, Sanofi SA, GlaxoSmithKline Plc, Amgen Inc, ANI Pharmaceuticals, Inc.
Order a Copy of This Market Report With Instant USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3810
Some Important TOC:
Market Overview
Global Market Landscape by Player
Players Profiles
Global Production, Revenue (Value), Price Trend by Type
Market Analysis by Application
Global Production, Consumption, Export, Import by Region (2013-2021)
Production, Revenue (Value) by Region (2013-2021)
Manufacturing Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Market Dynamics
Global Market Forecast (2021-2027)
Research Findings and Conclusion
Appendix
The following queries are answered in this comprehensive document:
1. What is the market size of the global and regional levels?
2. Which are the top countries and what is their market size?
3. Which are the growth opportunities in the coming years?
4. Which are the top players and what is their market share?
5. Which are the risk factors affecting market growth?
Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Antiandrogen Monotherapy Market 2021 Size, Status and Forecast | Business to 2027 appeared first on Gatorledger.
